Angiogenesis plays an important role in solid tumors and hematologic malignancies. The angiopoietins act as essential regulators in this process. We investigated the impact of circulating angiopoietin-1 (Ang-1), angiopoietin-2 (Ang-2) and soluble Tie2 (sTie2) on overall survival in patients with acute myeloid leukemia (AML). Ang-1, Ang-2 and sTie2 were measured in plasma samples from 68 AML patients and 11 controls using enzyme-linked immunosorbent assay. Circulating levels of Ang-2 and sTie2 (median (range): 1098.0 (361.4-4147.6) pg/ml and 3.40 (1.21-10.00) ng/ml, respectively) were significantly elevated in AML patients as compared to controls (307.9 (199.7-1225.0) pg/ml and 2.88 (1.71-3.29) ng/ml; Po0.001 and P ¼ 0.014). In a univariate Cox proportional hazards model, higher levels of Ang-2 and sTie2 were predictive of poor survival. In multivariate analyses, Ang-2 and cytogenetics proved to be independent prognostic factors, with a relative risk of 4.07 (95% confidence interval (CI) 1.88-8.81) and 2.70 (95% CI 1.25-5.81), respectively. The 3-year survival rate for AML patients with Ang-2 levelsX1495.6 pg/ml was only 14.7% compared to 64.7% for those with Ang-2 levelso1495.6 pg/ml. These data provide evidence that circulating Ang-2 represents an independent prognostic factor in AML and may be used as a prognostic tool in the risk-adapted management of AML.
Introduction
Angiogenesis plays a critical role in the development and growth of solid tumors and hematologic malignancies. 1, 2 Studies comparing the extent of bone marrow neovascularization in normal and neoplastic bone marrow have demonstrated significantly increased angiogenic activity in acute myeloid leukemia (AML). 3, 4 The elevated vessel density in neoplastic bone marrow is the result of the action of several angiogenic molecules released from leukemic blasts. 5 In turn, the expanded endothelial microenvironment is able to support leukemic cell survival and growth by secretion of hematopoietic growth factors. [6] [7] [8] Moreover, angiogenic mediators produced by AML cells also act through external or internal autocrine (intracrine) loops, thereby directly promoting cell survival, proliferation and disease progression independently from the mechanisms of angiogenesis. 9, 10 From the constantly growing list of angiogenic mediators, the members of the vascular endothelial growth factor (VEGF), basic fibroblast growth factor (bFGF) and angiopoietin (Ang) family have been established as the major regulators of tumorassociated angiogenesis. In AML, cellular VEGF is significantly upregulated in leukemic blasts 5, 11 and represents an adverse prognostic factor. 12 Similarly, elevated VEGF plasma levels have been linked with reduced survival, 13 lower complete remission (CR) rates 13 and the occurrence of extramedullary infiltration. 14 Likewise, bFGF is also overexpressed in AML bone marrow and stimulates leukemic cell proliferation in an autocrine manner. 10 However, Aguayo et al. 13 who reported elevated plasma levels of bFGF in patients with AML could not detect an association between bFGF and survival.
The angiopoietins constitute a family of angiogenic growth factors, which have been shown to be important regulators of angiogenesis and vascular stability. 15, 16 Ang-1 and its antagonist Ang-2 act via the receptor tyrosine kinase Tie2, which is expressed in endothelial cells (ECs) of the vasculature and in a subset of hematopoietic stem cells. [17] [18] [19] Binding of Ang-1 causes phosphorylation of Tie2 and ensures the integrity of the vasculature by promoting interactions between ECs and periendothelial support cells. 20 In contrast, the non-signal-transducing ligand Ang-2 disrupts Tie2 activation, resulting in vessel destabilization and facilitating the angiogenic response to mitogenic angiogenic factors. 16, 21 Consistent with their biological functions, Ang-1 is constitutively expressed throughout adult tissues providing a stabilizing signal, while normal post-natal Ang-2 expression is only observed at sites of active vascular remodeling. 16 In tumors, the balance between both angiopoietins is shifted toward Ang-2, rendering the vasculature susceptible for mitogenic growth factors such as VEGF or bFGF, and resulting in extensive neovascularization (reviewed by Tait and Jones 22 ). Our group and others have recently demonstrated the overexpression and prognostic significance of cellular Ang-2 expression in AML bone marrow 23 and isolated peripheral AML blasts. 24 Patients with high cellular Ang-2 expression showed a significant extended overall survival compared to patients with low Ang-2 expression. Previously, significant higher levels of Ang-2 have been reported in CD7 þ leukemia as compared to t(8;21)-positive AML, suggesting a cell-and karyotype-specific expression. 25 However, no data are so far available on blood levels of angiopoietins and their soluble receptor Tie2 (sTie2) in AML. Furthermore, while elevated blood levels of Ang-2 have been detected in patients with angiosarcoma, 26 breast cancer, 27 multiple myeloma and chronic myeloid leukemia, 28 to the best of our knowledge, there are no studies available on the prognostic value of soluble angiopoietins in any type of cancer.
In this study, we investigated the prognostic relevance of systemic levels of Ang-1, Ang-2 and sTie2 in a cohort of 68 AML patients treated with a standard chemotherapy regimen, and correlated angiogenic factor levels with clinicopathological features and overall survival.
Materials and methods

Patient samples
Pretherapeutic plasma levels of Ang-1, Ang-2 and sTie2 were measured in peripheral blood samples from 68 patients with newly diagnosed AML treated within the current German AML Cooperative Group (AMLCG) trial. Blood samples were obtained at diagnosis, 1-2 days before the initiation of induction chemotherapy, and stored at À801C before analysis at a later stage. Samples from 11 healthy individuals were collected and used as controls.
For remission induction, AML patients received a double induction regimen (either with TAD (thioguanine, standard dose cytarabine and daunorubicin) and HAM (high-dose cytarabine and mitoxantrone)) or two subsequent courses of HAM, irrespective of response to the first course. The second cycle was applied to patients older than 60 years only when a day-16 bone marrow aspiration revealed a significant residual blast infiltration (45% blasts in the hypoplastic bone marrow). Patients achieving a CR according to standard criteria, 29 underwent consolidation therapy consisting of one-cycle TAD. Following consolidation, patients received either 3 years of myelosuppressive maintenance therapy or autologous stem cell transplantation. 30 Two patients with acute promyelocytic leukemia received all-trans retinoic acid in addition to chemotherapy. A total of eight patients underwent allogeneic stem cell transplantation. All patients gave their informed consent and the study received approval from the Local Ethics Committee. Patient characteristics are summarized in Table 1 .
Enzyme-linked immunosorbent assays
Enzyme-linked immunosorbent assays (ELISA) were performed using commercially available kits from R&D Systems (Minneapolis, MN, USA). Briefly, patient samples were collected using the anticoagulant ethylenediaminetetraacetic acid (EDTA) and stored at À801C. Plasma samples were added to separate microplates, each containing a specific antibody for Ang-1, Ang-2 or sTie2. Mixtures were incubated at room temperature for 2 h. Plates were washed four times to remove unbound antigen. Enzyme-linked polyclonal antibodies specific for each angiogenic factor were then added and the mixture incubated for 2 h, followed by another washing step. Subsequently, the substrate solution was added to the wells. Color development was stopped, and the intensity of color was measured and compared with a standard curve. Optical density of each well was determined at 570 nm according to the manufacturer's instructions.
Statistics
Differences in angiogenic factor levels between AML and control groups, and associations between angiogenic factor levels and patient characteristics were analyzed using the Mann-Whitney rank sum test for independent groups. Statistical significance of overall differences between more than two groups was analyzed by the Kruskal-Wallis test. In addition, correlations between continuous variables were assessed by the Spearman rank correlation coefficient (r s ).
Survival curves were estimated using the Kaplan-Meier method, and the log-rank test was used to compare survival between groups. Overall survival was the primary outcome studied and was calculated from the date of first diagnosis to death from any cause. Patients who did not suffer an event within the follow-up period were censored at the date of last contact. Univariate and multivariate Cox proportional hazards regression analyses were performed to evaluate the predictive effect of each angiogenic factor. Optimal cutoff points were identified by recursive partitioning. 31 Variables found to be statistically significant at a 10% level in the univariate analyses were included in the multivariate model. Different models were established, incorporating angiogenic factors as categorical or as continuous variables, respectively. Based on the established models, variable selection was performed by different forward and backward procedures. The results of all applied approaches were comparable. Two-sided P-values o0.05 were considered significant. All calculations were performed using the software packages SPSS (SPSS Inc., Chicago, IL, USA) and S-PLUS (Insightful Corp., Seattle, WA, USA).
Results
Plasma levels of Ang-1, Ang-2 and sTie2 in AML patients and healthy donors Levels of Ang-1, Ang-2 and sTie2 have been measured in pretherapeutic plasma samples of patients with AML and healthy individuals. Circulating levels of Ang-2 and sTie2 were significantly elevated in AML patients as compared to controls (Table 2 ). In contrast, levels of Ang-1 did not significantly differ between both groups. Spearman correlation coefficients have been calculated between Ang-1, Ang-2 and sTie2 levels. Ang-2 levels were positively correlated with sTie2 levels (r ¼ 0.486, Po0.001). However, there were no associations between Ang-1 and Ang-2 or Ang-1 and sTie2 (P ¼ 0.636 and 0.917, respectively).
Association between plasma levels of Ang-1, Ang-2 and sTie2, and clinicopathological features
No statistical association between the levels of Ang-1, Ang-2 and sTie2, and the variable patients' sex or age at first diagnosis of AML were observed (P40.1 for each variable, MannWhitney test). Levels of Ang-1, Ang-2 and sTie2 did not significantly differ between different AML subtypes as defined by the French-American-British (FAB) classification (P40.1 for Furthermore, we tested if circulating levels of Ang-1, Ang-2 and sTie2 at first diagnosis could predict the achievement of a CR following induction therapy. From the 68 patients of our study population receiving intensive induction therapy, 47 (69%) achieved a CR. Levels of Ang-1 and sTie2 in these patients did not significantly differ from those observed in patients not achieving a CR (P40.1 for each variable, MannWhitney test); however, Ang-2 levels showed a tendency to be higher in AML patients not reaching a CR (medians 1627.4 vs 1045.3 pg/ml, P ¼ 0.091).
Association between plasma levels of Ang-1, Ang-2 and sTie2, and overall survival To determine the relationship of circulating Ang1, Ang-2 and sTie2, and prognosis in AML, we initially performed univariate Cox proportional hazards analyses. As expected, the clinicopathological variables karyotype (unfavorable vs intermediate, P ¼ 0.018), WBC (P ¼ 0.044) and LDH (P ¼ 0.031) displayed prognostic significance (Table 3) . Furthermore, using the dichotomous cutoff levels identified by recursive partitioning, the angiogenic factors Ang-2 and sTie2 were significantly associated with survival ( Table 3 ). The relative risk (RR) of death was significantly higher for patients with Ang-2 levelsX1495.6 pg/ml (RR 3.70, 95% confidence interval (CI) 1.76-7.78; P ¼ 0.001) and for patients with sTie2 levelsX4.25 ng/ml (RR 2.22, 95% CI 1.05-4.69; P ¼ 0.036). In contrast, we could not detect a significant prognostic role for circulating Ang-1. However, higher Ang-1 levels (X469.2 pg/ ml) tended to be associated with a favorable outcome (RR 0.28, 95% CI 0.07-1.17; P ¼ 0.081).
Subsequently, we performed multivariate Cox regression analyses incorporating all variables showing a significant association with survival in the univariate model at a 10% level (karyotype, percentage of bone marrow infiltration, WBC, LDH, Ang-1, Ang-2 and sTie2). After variable selection, karyotype and Ang-2 were identified to be the only prognostic factors with significant independent impact on survival (P ¼ 0.011 and Po0.001, respectively, Table 4 ). Comparable results were obtained when Ang-1, Ang-2 and sTie2 were included in the multivariate model either as continuous variables (Ang-2: P ¼ 0.002) or as dichotomous variables using the median as the cutoff value (Ang-2: RR 2.49, 95% CI 1.16-5.36; P ¼ 0.020). According to our model, the relative risk of death was more than 2.5 times higher for AML patients with unfavorable cytogenetics Table 2 Circulating levels of Ang-1, Ang-2 and sTie2 in AML patients at first diagnosis and healthy controls Angiopoietin-2, a prognostic factor in AML C Schliemann et al (RR 2.70, 95% CI 1.25-5.81) and four times higher for patients with Ang-2 levelsX1495.6 pg/ml ( 4.07, 95% CI 1.88-8.81) ( Table 4 ). The 3-year survival rate for AML patients with high levels of Ang-2 was only 14.7% compared to 64.7% for those with low levels of Ang-2. Figure 1 illustrates the Kaplan-Meier curves of overall survival stratified for Ang-2 levels and cytogenetic status. Finally, we re-analyzed data after censoring patients who received allogeneic stem cell transplantation at the date of cell infusion to exclude the influence of transplantation-related death. Again, this additional analysis did not change the conclusion, and the variables Ang-2 (RR 4.08, 95% CI 1.73-9.63; P ¼ 0.001) and karyotype proved to be the only independent predictors of survival.
Associations between plasma levels of Ang-2 and mitogenic angiogenic factors Since Ang-2 is known to exert its functions in concert with mitogenic angiogenic factors, plasma levels of VEGF and bFGF have also been analyzed in the AML cohort. However, no significant correlations were found between Ang-2 and VEGF or bFGF (r s ¼ 0.221, P ¼ 0.072 and r s ¼ À0.163, P ¼ 0.187, respectively). Neither VEGF nor bFGF levels displayed significant associations with survival in univariate analyses using optimal cutoff values derived from recursive partitioning (P40.1 for both variables). Furthermore, we investigated the prognostic impact of Ang-2 in the subgroups of AML patients expressing high or low levels of either VEGF or bFGF as defined by the median. In all four subgroups, the negative prognostic impact of Ang-2 was equally detectable (RR 3.15-4.63; P ¼ 0.007-0.025, based on optimal cutoffs from recursive partitioning).
Discussion
The prognostic impact of angiogenic growth factors in hematologic malignancies has gained significant attention over the past few years. In this study, we were able to detect Ang-1, Ang-2 and sTie2 in the plasma of most patients with newly diagnosed AML. Pretherapeutic levels of circulating Ang-2 and sTie2 were significantly higher in AML patients as compared to normal controls. These findings are in line with recent observations of elevated Ang-2 and sTie2 levels in patients with chronic myeloid leukemia and multiple myeloma. 28 Furthermore, we could demonstrate a strong correlation between systemic levels of Ang-2 and overall survival in intensively treated AML patients. Patients with high plasma levels of Ang-2 displayed a significantly worse overall survival than those with low levels. Multivariate analyses revealed that the prognostic impact of circulating Ang-2 levels was independent from established prognostic markers such as cytogenetics, WBC or LDH. Notably, Ang-2 displayed a prognostic value being at least in a similar range as the value of the variable cytogenetics, which is generally accepted as the most important risk factor in AML.
Our findings are in apparent contrast to Loges et al. 24 and our group's recently published studies, in which cellular Ang-2 expression could be consistently identified as an independent predictor of a favorable prognosis in AML patients. 23, 24 Indeed, the results of this study were unexpected on the background of the two mentioned reports and provide another example that intracellular levels of angiogenic factors may not reflect their blood levels. 33 However, the observed differences could be explained in part by the source of circulating Ang-2, which most likely originates not only from leukemic blasts but also from other cell types such as endothelial cells. In fact, it is entirely possible that a predominant proportion of circulating Ang-2 Table 4 Multivariate Cox proportional hazards model for overall survival in AML patients Intermediate Figure 1 Kaplan-Meier curves of overall survival of AML patients according to Ang-2 levels and cytogenetic status. AML patients with Ang-2 levelsX1495.6 pg/ml displayed significantly worse survival rates than those with Ang-2 levelso1495.6 pg/ml. AML, acute myeloid leukemia; Ang-2, angiopoietin-2.
Angiopoietin-2, a prognostic factor in AML C Schliemann et al could be secreted by activated bone marrow endothelial cells, given the increased angiogenic activity in the leukemic bone marrow. Furthermore, it is conceivable that Ang-2 could also be released by the endothelium of the normal vasculature upon dysregulated stimulation by leukemic blasts. However, on the other hand, blood levels of Ang-2 and sTie2 in our study were strongly associated with the extent of bone marrow blast infiltration, WBC and LDH, providing indirect evidence that the leukemic blasts themselves at least significantly contributed to the plasma levels of the tested angiogenic factors. Taken together, the exact origins of Ang-2 and its soluble receptor in the bloodstream remain to be elucidated, and further research into this issue is required. Measurement of changes of circulating Ang-2 levels during the course of induction chemotherapy and in CR might be of particular interest. The different methods used for measurement of angiogenic factors in this report and the abovementioned studies 23, 24 might also have contributed to the differential prognostic impact of cellular and systemic Ang-2 levels. Indeed, angiopoietin signaling in AML most likely comprises paracrine, autocrine and, eventually, even intracrine (internal autocrine) loops. There is growing evidence that AML blasts also express the angiopoietin receptor Tie2 23, 24, 34 and establish an autocrine angiopoietin/Tie2 loop, 35 as already demonstrated for VEGF 9,36 or bFGF. 10 At least in endothelial cells, Ang-2 has also been shown to act through an internal autocrine (intracrine) loop. 37 Therefore, it is justified to argue that Ang-2 may exert its biological functions in different compartments, thereby differentially influencing the clinical course of AML in the context of intensive cytotoxic treatment. As a result, different prognostic values may be observed when investigating either cellassociated or circulating Ang-2 separately. Unfortunately, samples of AML blasts were unavailable in our study to confirm a reciprocal prognostic impact of intracellular and extracellular Ang-2 expression.
To the best of our knowledge, the prognostic relevance of circulating Ang-2 in AML, other hematologic malignancies or solid tumors has not been published before. However, elevated levels of circulating Ang-2 have been detected and linked with angiogenesis in malignancies such as angiosarcoma, 26 breast cancer, 27 multiple myeloma and chronic myeloid leukemia. 28 In analogy, high levels of Ang-2 in AML may contribute to angiogenesis in the bone marrow, in the presence of mitogenic angiogenic mediators, thereby facilitating leukemic blast proliferation and disease progression. 21 In this sense, Ang-2 in circulation may eventually represent an attractive therapeutic target when introducing antiangiogenic strategies into the treatment of AML. The therapeutic efficacy of blocking Ang-2 has already been demonstrated in solid tumors, 38 and a recombinant Fc fusion protein directed against the action of angiopoietins is currently being evaluated in a phase I study in patients with advanced solid tumors (http://www.clinicaltrials. gov/ct/show/NCT00102830). In fact, our results seem to argue against a therapeutic administration of Ang-2 in AML, as previously suggested, on the basis of the favorable prognostic impact of cellular Ang-2 observed in RNA expression studies. 24 In summary, the results of our study clearly demonstrate the independent prognostic significance of circulating Ang-2 in AML. A better understanding of the precise functions of angiopoietin signaling pathways in AML may open new avenues for therapeutic interventions. If confirmed in large AML trials, measurement of Ang-2 concentrations at disease presentation may eventually find its way into clinical routine as an additional prognostic tool in the risk-stratified management of AML.
